ERBB2 and cancer: The finding that HER2 overexpressing cancers are particularly sensitive to modification of Cys242 of PI3Kα by the molecules described here and also BBO-10203 highlights the surprising potential for this strategy to benefit patients whose disease is driven by this signaling pathway.